JAK1 Antibody (A-9): sc-1677

JAK1 Antibody (A-9) is a mouse monoclonal IgG2b kappa light chain antibody that detects JAK1 of mouse, rat, and human origin by WB, IP, IF, IHC, and ELISA. JAK1 Antibody (A-9) is available in both non-conjugated and various conjugated forms, including agarose, HRP, PE, FITC, and multiple Alexa Fluor® conjugates. JAK1, or Janus kinase 1, is a crucial member of the non-receptor Janus tyrosine kinase family, which plays a vital role in mediating cellular responses to cytokine signaling in the lympho-hematopoietic system. JAK1 is primarily located in the cytoplasm and is recruited to the membrane upon activation of cytokine receptors. This localization is essential for JAK1′s function, as JAK1 interacts with receptor-associated proteins and initiates downstream signaling cascades. Upon stimulation by immunological signals such as interferons and cytokines, JAK1 phosphorylates signal transducer and activator of transcription (Stat) proteins, leading to their dimerization and translocation to the nucleus, where they regulate gene expression. The phosphorylation of specific tyrosine residues, particularly at positions 1022 and 1023, is critical for JAK1′s catalytic activation and subsequent signaling events. The canonical JAK-Stat pathway is integral to maintaining immune homeostasis, promoting cell proliferation, differentiation, and survival, while also providing host defense against pathogens. Dysregulation of JAK-Stat signaling has been implicated in various inflammatory diseases, making JAK1 a promising target for therapeutic intervention in anti-inflammatory strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

JAK1 Antibody (A-9) References:

1. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes.  |  Kotenko, SV. and Pestka, S. 2000. Oncogene. 19: 2557-65. PMID: 10851054
2. Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.  |  Delgado, M. and Ganea, D. 2000. J Immunol. 165: 3051-7. PMID: 10975815
3. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.  |  Shin, DS., et al. 2017. Cancer Discov. 7: 188-201. PMID: 27903500
4. Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function.  |  Gruber, CN., et al. 2020. Immunity. 53: 672-684.e11. PMID: 32750333
5. Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages.  |  Runtsch, MC., et al. 2022. Cell Metab. 34: 487-501.e8. PMID: 35235776
6. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine.  |  Kavanagh, ME., et al. 2022. Nat Chem Biol. 18: 1388-1398. PMID: 36097295
7. Successful treatment of JAK1-associated inflammatory disease.  |  Fayand, A., et al. 2023. J Allergy Clin Immunol. 152: 972-983. PMID: 37343845
8. The Jak-STAT pathway: specific signal transduction from the cell membrane to the nucleus.  |  Heim, MH. 1996. Eur J Clin Invest. 26: 1-12. PMID: 8682149
9. Interferon-alpha-dependent activation of Tyk2 requires phosphorylation of positive regulatory tyrosines by another kinase.  |  Gauzzi, MC., et al. 1996. J Biol Chem. 271: 20494-500. PMID: 8702790
10. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.  |  Liu, KD., et al. 1997. Curr Biol. 7: 817-26. PMID: 9382798
11. Jaks, Stats and the immune system.  |  Decker, T. and Meinke, A. 1997. Immunobiology. 198: 99-111. PMID: 9442382
12. Jaks and STATs: biological implications.  |  Leonard, WJ. and O'Shea, JJ. 1998. Annu Rev Immunol. 16: 293-322. PMID: 9597132

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-JAK1 Antibody (A-9) has 26 citations in a variety of scientific publications.

Primary antibodies like Anti-JAK1 Antibody (A-9) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

JAK1 Antibody (A-9) Specifications

Alternate Product Name: JAK1

Product Clone Name: A-9

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2b kappa light chain

Amino Acids: 796-815

Epitope Target: JAK1

Epitope Species: mouse

Product Reactivity/Detection: JAK1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: equine, canine, bovine and porcine

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2b kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 26 citations in various scientific publications

Available Conjugates/Forms for JAK1 Antibody (A-9): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, P: Blocking Peptide, PE: Phycoerythrin